A type of mutation that 'switches on' inflammatory signalling pathways in human liver tumours is described in a paper in Nature. Similar mutations may occur in other inflammatory epithelial cancers.
Jessica Zucman-Rossi and colleagues studied human inflammatory hepatocellular adenomas (IHCAs), benign liver tumours with a strong inflammatory signature. 'Gain-of-function' mutations in the gp130 signalling component of the interleukin-6 receptor - a pro-inflammatory signalling pathway - were found in around 60% of IHCAs.
The gp130 alterations were accompanied by mutations that activate beta-catenin, a molecule already implicated in the development of liver cancer. So it's thought that the two mutations cooperate to promote tumour formation.
Jessica Zucman-Rossi (Institut National de la Sante et la Recherce Medicale, Paris, France)
Abstract available online.
(C) Nature press release.
Message posted by: Trevor M. D'Souza
Bookmark and Share this page (what is this?)
Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.
Use the links below to share this article on the social bookmarking site of your choice.
Read more about social bookmarking at Wikipedia - Social Bookmarking